ID   PRDX1_HUMAN             Reviewed;         199 AA.
AC   Q06830; B5BU26; D3DPZ8; P35703; Q2V576; Q5T154; Q5T155;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=Peroxiredoxin-1;
DE            EC=1.11.1.15;
DE   AltName: Full=Natural killer cell-enhancing factor A;
DE            Short=NKEF-A;
DE   AltName: Full=Proliferation-associated gene protein;
DE            Short=PAG;
DE   AltName: Full=Thioredoxin peroxidase 2;
DE   AltName: Full=Thioredoxin-dependent peroxide reductase 2;
GN   Name=PRDX1; Synonyms=PAGA, PAGB, TDPX2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8496166;
RA   Prosperi M.T., Ferbus D., Karczinski I., Goubin G.;
RT   "A human cDNA corresponding to a gene overexpressed during cell
RT   proliferation encodes a product sharing homology with amoebic and
RT   bacterial proteins.";
RL   J. Biol. Chem. 268:11050-11056(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8026862; DOI=10.1007/BF00188176;
RA   Shau H., Butterfield L.H., Chiu R., Kim A.;
RT   "Cloning and sequence analysis of candidate human natural killer-
RT   enhancing factor genes.";
RL   Immunogenetics 40:129-134(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-62.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 17-35; 93-136; 141-151 AND 159-190, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [11]
RP   OVEROXIDATION AT CYS-52.
RX   PubMed=12059788; DOI=10.1042/BJ20020525;
RA   Wagner E., Luche S., Penna L., Chevallet M., van Dorsselaer A.,
RA   Leize-Wagner E., Rabilloud T.;
RT   "A method for detection of overoxidation of cysteines: peroxiredoxins
RT   are oxidized in vivo at the active-site cysteine during oxidative
RT   stress.";
RL   Biochem. J. 366:777-785(2002).
RN   [12]
RP   PHOSPHORYLATION AT THR-90, AND MUTAGENESIS OF THR-90.
RX   PubMed=11986303; DOI=10.1074/jbc.M110432200;
RA   Chang T.-S., Jeong W., Choi S.Y., Yu S., Kang S.W., Rhee S.G.;
RT   "Regulation of peroxiredoxin I activity by Cdc2-mediated
RT   phosphorylation.";
RL   J. Biol. Chem. 277:25370-25376(2002).
RN   [13]
RP   OVEROXIDATION AT CYS-52.
RX   PubMed=12161445; DOI=10.1074/jbc.M206626200;
RA   Yang K.S., Kang S.W., Woo H.A., Hwang S.C., Chae H.Z., Kim K.,
RA   Rhee S.G.;
RT   "Inactivation of human peroxiredoxin I during catalysis as the result
RT   of the oxidation of the catalytic site cysteine to cysteine-sulfinic
RT   acid.";
RL   J. Biol. Chem. 277:38029-38036(2002).
RN   [14]
RP   RETROREDUCTION OF CYS-52, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12853451; DOI=10.1074/jbc.M305161200;
RA   Chevallet M., Wagner E., Luche S., van Dorsselaer A., Leize-Wagner E.,
RA   Rabilloud T.;
RT   "Regeneration of peroxiredoxins during recovery after oxidative
RT   stress: only some overoxidized peroxiredoxins can be reduced during
RT   recovery after oxidative stress.";
RL   J. Biol. Chem. 278:37146-37153(2003).
RN   [15]
RP   RETROREDUCTION OF CYS-52, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12714748; DOI=10.1126/science.1080273;
RA   Woo H.A., Chae H.Z., Hwang S.C., Yang K.S., Kang S.W., Kim K.,
RA   Rhee S.G.;
RT   "Reversing the inactivation of peroxiredoxins caused by cysteine
RT   sulfinic acid formation.";
RL   Science 300:653-656(2003).
RN   [16]
RP   INTERACTION WITH SESN1 AND SESN2.
RX   PubMed=15105503; DOI=10.1126/science.1095569;
RA   Budanov A.V., Sablina A.A., Feinstein E., Koonin E.V., Chumakov P.M.;
RT   "Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of
RT   bacterial AhpD.";
RL   Science 304:596-600(2004).
RN   [17]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-7; LYS-16; LYS-27 AND
RP   LYS-35, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-32, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-32, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-185, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Involved in redox regulation of the cell. Reduces
CC       peroxides with reducing equivalents provided through the
CC       thioredoxin system but not from glutaredoxin. May play an
CC       important role in eliminating peroxides generated during
CC       metabolism. Might participate in the signaling cascades of growth
CC       factors and tumor necrosis factor-alpha by regulating the
CC       intracellular concentrations of H(2)O(2). Reduces an
CC       intramolecular disulfide bond in GDPD5 that gates the ability to
CC       GDPD5 to drive postmitotic motor neuron differentiation (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: 2 R'-SH + ROOH = R'-S-S-R' + H(2)O + ROH.
CC   -!- SUBUNIT: Homodimer; disulfide-linked, upon oxidation (By
CC       similarity). May form heterodimers with AOP2. Interacts with
CC       GDPD5; forms a mixed-disulfide with GDPD5 (By similarity).
CC       Interacts with SESN1 and SESN2 (PubMed:15105503). {ECO:0000250,
CC       ECO:0000269|PubMed:15105503}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=3; IntAct=EBI-353193, EBI-608057;
CC       P60484:PTEN; NbExp=7; IntAct=EBI-353193, EBI-696162;
CC       Q13043:STK4; NbExp=11; IntAct=EBI-353193, EBI-367376;
CC       P54274:TERF1; NbExp=2; IntAct=EBI-353193, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17081065}.
CC       Melanosome {ECO:0000269|PubMed:17081065}. Note=Identified by mass
CC       spectrometry in melanosome fractions from stage I to stage IV.
CC   -!- INDUCTION: Constitutively expressed in most human cells; is
CC       induced to higher levels upon serum stimulation in untransformed
CC       and transformed cells.
CC   -!- PTM: Phosphorylated on Thr-90 during the M-phase, which leads to a
CC       more than 80% decrease in enzymatic activity.
CC       {ECO:0000269|PubMed:11986303}.
CC   -!- MISCELLANEOUS: The active site is the redox-active Cys-52 oxidized
CC       to Cys-SOH. Cys-SOH rapidly reacts with Cys-173-SH of the other
CC       subunit to form an intermolecular disulfide with a concomitant
CC       homodimer formation. The enzyme may be subsequently regenerated by
CC       reduction of the disulfide by thioredoxin.
CC   -!- MISCELLANEOUS: Inactivated upon oxidative stress by overoxidation
CC       of Cys-52 to Cys-SO(2)H and Cys-SO(3)H. Cys-SO(2)H is retroreduced
CC       to Cys-SOH after removal of H(2)O(2), while Cys-SO(3)H may be
CC       irreversibly oxidized.
CC   -!- SIMILARITY: Belongs to the AhpC/TSA family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAI13097.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAGID266.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/prdx1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X67951; CAA48137.1; -; mRNA.
DR   EMBL; L19184; AAA50464.1; -; mRNA.
DR   EMBL; BT019740; AAV38545.1; -; mRNA.
DR   EMBL; CR407652; CAG28580.1; -; mRNA.
DR   EMBL; DQ297142; ABB84465.1; -; Genomic_DNA.
DR   EMBL; AB451262; BAG70076.1; -; mRNA.
DR   EMBL; AB451388; BAG70202.1; -; mRNA.
DR   EMBL; AL451136; CAI13095.1; -; Genomic_DNA.
DR   EMBL; AL451136; CAI13096.1; -; Genomic_DNA.
DR   EMBL; AL451136; CAI13097.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471059; EAX06975.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06976.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06978.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06979.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06980.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06981.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06982.1; -; Genomic_DNA.
DR   EMBL; BC007063; AAH07063.1; -; mRNA.
DR   EMBL; BC021683; AAH21683.1; -; mRNA.
DR   CCDS; CCDS522.1; -.
DR   PIR; A46711; A46711.
DR   RefSeq; NP_001189360.1; NM_001202431.1.
DR   RefSeq; NP_002565.1; NM_002574.3.
DR   RefSeq; NP_859047.1; NM_181696.2.
DR   RefSeq; NP_859048.1; NM_181697.2.
DR   UniGene; Hs.180909; -.
DR   UniGene; Hs.731900; -.
DR   PDB; 2RII; X-ray; 2.60 A; A/B=1-199.
DR   PDB; 3HY2; X-ray; 2.10 A; A/B=1-199.
DR   PDB; 4XCS; X-ray; 2.10 A; A/B/C/D/E/F=1-199.
DR   PDBsum; 2RII; -.
DR   PDBsum; 3HY2; -.
DR   PDBsum; 4XCS; -.
DR   ProteinModelPortal; Q06830; -.
DR   SMR; Q06830; -.
DR   BioGrid; 111089; 131.
DR   DIP; DIP-33152N; -.
DR   IntAct; Q06830; 61.
DR   MINT; MINT-4999060; -.
DR   STRING; 9606.ENSP00000262746; -.
DR   ChEMBL; CHEMBL5315; -.
DR   PeroxiBase; 4501; Hs2CysPrx01.
DR   iPTMnet; Q06830; -.
DR   PhosphoSitePlus; Q06830; -.
DR   SwissPalm; Q06830; -.
DR   BioMuta; PRDX1; -.
DR   DMDM; 548453; -.
DR   DOSAC-COBS-2DPAGE; Q06830; -.
DR   OGP; Q06830; -.
DR   SWISS-2DPAGE; Q06830; -.
DR   UCD-2DPAGE; Q06830; -.
DR   EPD; Q06830; -.
DR   MaxQB; Q06830; -.
DR   PaxDb; Q06830; -.
DR   PeptideAtlas; Q06830; -.
DR   PRIDE; Q06830; -.
DR   TopDownProteomics; Q06830; -.
DR   DNASU; 5052; -.
DR   Ensembl; ENST00000262746; ENSP00000262746; ENSG00000117450.
DR   Ensembl; ENST00000319248; ENSP00000361152; ENSG00000117450.
DR   GeneID; 5052; -.
DR   KEGG; hsa:5052; -.
DR   UCSC; uc001coa.4; human.
DR   CTD; 5052; -.
DR   DisGeNET; 5052; -.
DR   GeneCards; PRDX1; -.
DR   HGNC; HGNC:9352; PRDX1.
DR   HPA; CAB004682; -.
DR   HPA; HPA007730; -.
DR   MIM; 176763; gene.
DR   neXtProt; NX_Q06830; -.
DR   OpenTargets; ENSG00000117450; -.
DR   PharmGKB; PA33722; -.
DR   eggNOG; KOG0852; Eukaryota.
DR   eggNOG; COG0450; LUCA.
DR   GeneTree; ENSGT00390000004653; -.
DR   HOVERGEN; HBG000286; -.
DR   InParanoid; Q06830; -.
DR   KO; K13279; -.
DR   OMA; TAEVHFA; -.
DR   OrthoDB; EOG091G0IE5; -.
DR   PhylomeDB; Q06830; -.
DR   TreeFam; TF105181; -.
DR   BRENDA; 1.11.1.15; 2681.
DR   Reactome; R-HSA-3299685; Detoxification of Reactive Oxygen Species.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   SIGNOR; Q06830; -.
DR   ChiTaRS; PRDX1; human.
DR   EvolutionaryTrace; Q06830; -.
DR   GeneWiki; Peroxiredoxin_1; -.
DR   GenomeRNAi; 5052; -.
DR   PRO; PR:Q06830; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117450; -.
DR   CleanEx; HS_PRDX1; -.
DR   ExpressionAtlas; Q06830; baseline and differential.
DR   Genevisible; Q06830; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0004601; F:peroxidase activity; IDA:MGI.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0008379; F:thioredoxin peroxidase activity; IDA:BHF-UCL.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0045454; P:cell redox homeostasis; IEA:InterPro.
DR   GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0042744; P:hydrogen peroxide catabolic process; IDA:BHF-UCL.
DR   GO; GO:0030101; P:natural killer cell activation; IDA:UniProtKB.
DR   GO; GO:0042267; P:natural killer cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0042345; P:regulation of NF-kappaB import into nucleus; IEA:Ensembl.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; IEA:Ensembl.
DR   GO; GO:0019430; P:removal of superoxide radicals; IEA:Ensembl.
DR   GO; GO:0000302; P:response to reactive oxygen species; TAS:Reactome.
DR   GO; GO:0001895; P:retina homeostasis; IEP:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   InterPro; IPR000866; AhpC/TSA.
DR   InterPro; IPR024706; Peroxiredoxin_AhpC-typ.
DR   InterPro; IPR019479; Peroxiredoxin_C.
DR   InterPro; IPR012336; Thioredoxin-like_fold.
DR   InterPro; IPR013766; Thioredoxin_domain.
DR   Pfam; PF10417; 1-cysPrx_C; 1.
DR   Pfam; PF00578; AhpC-TSA; 1.
DR   PIRSF; PIRSF000239; AHPC; 1.
DR   SUPFAM; SSF52833; SSF52833; 1.
DR   PROSITE; PS51352; THIOREDOXIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Antioxidant; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disulfide bond; Isopeptide bond;
KW   Oxidoreductase; Peroxidase; Phosphoprotein; Polymorphism;
KW   Redox-active center; Reference proteome; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:25944712}.
FT   CHAIN         2    199       Peroxiredoxin-1.
FT                                /FTId=PRO_0000135076.
FT   DOMAIN        6    165       Thioredoxin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00691}.
FT   ACT_SITE     52     52       Cysteine sulfenic acid (-SOH)
FT                                intermediate.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:25944712}.
FT   MOD_RES       7      7       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      16     16       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      27     27       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      32     32       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      35     35       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      35     35       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P35700}.
FT   MOD_RES      90     90       Phosphothreonine; by CDK1.
FT                                {ECO:0000269|PubMed:11986303}.
FT   MOD_RES     136    136       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P35700}.
FT   DISULFID     52     52       Interchain (with C-173); in linked form.
FT   DISULFID    173    173       Interchain (with C-52); in linked form.
FT   CROSSLNK    185    185       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   VARIANT      62     62       R -> G (in dbSNP:rs34034070).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_025050.
FT   MUTAGEN      90     90       T->A: Abolishes phosphorylation by CDK1;
FT                                30% reduction in enzymatic activity.
FT                                {ECO:0000269|PubMed:11986303}.
FT   MUTAGEN      90     90       T->D: 87% reduction in enzymatic
FT                                activity. {ECO:0000269|PubMed:11986303}.
FT   CONFLICT    147    147       L -> P (in Ref. 2). {ECO:0000305}.
FT   CONFLICT    149    150       VG -> CC (in Ref. 2). {ECO:0000305}.
FT   CONFLICT    189    189       Q -> P (in Ref. 2). {ECO:0000305}.
FT   CONFLICT    191    191       S -> T (in Ref. 2). {ECO:0000305}.
FT   STRAND        2      5       {ECO:0000244|PDB:4XCS}.
FT   STRAND       16     20       {ECO:0000244|PDB:3HY2}.
FT   STRAND       26     30       {ECO:0000244|PDB:3HY2}.
FT   HELIX        31     34       {ECO:0000244|PDB:3HY2}.
FT   STRAND       37     43       {ECO:0000244|PDB:3HY2}.
FT   HELIX        48     50       {ECO:0000244|PDB:4XCS}.
FT   HELIX        54     61       {ECO:0000244|PDB:3HY2}.
FT   HELIX        63     68       {ECO:0000244|PDB:3HY2}.
FT   STRAND       71     79       {ECO:0000244|PDB:3HY2}.
FT   HELIX        81     88       {ECO:0000244|PDB:3HY2}.
FT   HELIX        92     94       {ECO:0000244|PDB:3HY2}.
FT   STRAND      104    106       {ECO:0000244|PDB:3HY2}.
FT   HELIX       111    115       {ECO:0000244|PDB:3HY2}.
FT   TURN        121    123       {ECO:0000244|PDB:3HY2}.
FT   STRAND      124    126       {ECO:0000244|PDB:3HY2}.
FT   STRAND      128    133       {ECO:0000244|PDB:3HY2}.
FT   STRAND      137    145       {ECO:0000244|PDB:3HY2}.
FT   HELIX       153    168       {ECO:0000244|PDB:3HY2}.
FT   STRAND      169    171       {ECO:0000244|PDB:2RII}.
FT   HELIX       181    183       {ECO:0000244|PDB:3HY2}.
SQ   SEQUENCE   199 AA;  22110 MW;  8F68E56D75BF5304 CRC64;
     MSSGNAKIGH PAPNFKATAV MPDGQFKDIS LSDYKGKYVV FFFYPLDFTF VCPTEIIAFS
     DRAEEFKKLN CQVIGASVDS HFCHLAWVNT PKKQGGLGPM NIPLVSDPKR TIAQDYGVLK
     ADEGISFRGL FIIDDKGILR QITVNDLPVG RSVDETLRLV QAFQFTDKHG EVCPAGWKPG
     SDTIKPDVQK SKEYFSKQK
//
